<h1>Paper Summary</h1>

<!--META_START-->

<p>Title: PIK3R1 W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma  </p>

<p>Authors: Concetta D’Ambrosio, Jessica Erriquez, Maddalena Arigoni, Sonia Capellero, Gloria Mittica, Eleonora Ghisoni, Fulvio Borella, Dionyssios Katsaros, Silvana Privitera, Marisa Ribotta, Elena Maldi, Giovanna Di Nardo, Enrico Berrino, Tiziana Venesio, Riccardo Ponzone, Marco Vaira, Douglas Hall, Mercedes Jimenez-Linan, Anna L. Paterson, Raffaele A. Calogero, James D. Brenton, Giorgio Valabrega, Maria Flavia Di Renzo, Martina Olivero  </p>

<p>DOI: 10.3390/cells9020442  </p>

<p>Year: 2020  </p>

<p>Publication Type: Journal Article  </p>

<p>Discipline/Domain: Oncology / Cancer Genomics  </p>

<p>Subdomain/Topic: Precision oncology; actionable mutations; ovarian cancer; PI3K pathway  </p>

<p>Eligibility: Eligible  </p>

<p>Overall Relevance Score: 82  </p>

<p>Operationalization Score: 90  </p>

<p>Contains Definition of Actionability: Yes (explicit and implicit)  </p>

<p>Contains Systematic Features/Dimensions: Yes  </p>

<p>Contains Explainability: Partial  </p>

<p>Contains Interpretability: Yes  </p>

<p>Contains Framework/Model: Yes (patient-derived xenograft validation approach)  </p>

<p>Operationalization Present: Yes  </p>

<p>Primary Methodology: Experimental (patient-derived xenografts, ex vivo/in vivo drug testing)  </p>

<p>Study Context: High grade serous epithelial ovarian carcinoma (HGS-EOC)  </p>

<p>Geographic/Institutional Context: Italy (Candiolo Cancer Institute, University of Torino) &amp; UK (University of Cambridge, CRUK Cambridge Institute)  </p>

<p>Target Users/Stakeholders: Cancer researchers, molecular oncologists, clinical trial designers, translational oncology labs  </p>

<p>Primary Contribution Type: Empirical validation of rare actionable mutation in ovarian cancer  </p>

<p>CL: Yes  </p>

<p>CR: Yes  </p>

<p>FE: Yes  </p>

<p>TI: No  </p>

<p>EX: Partial  </p>

<p>GA: Yes  </p>

<p>Reason if Not Eligible: n/a  </p>

<!--META_END-->

<p><strong>Contextual Background:</strong>  </p>

<p>The study focuses on identifying and validating rare but actionable genetic mutations in HGS-EOC, particularly those in the “long tail” of cancer driver alterations. Patient-derived xenograft (PDX) and derived tumour cell (PDTC) models were used to investigate the functional and therapeutic relevance of the PIK3R1 W624R mutation, a rare alteration in the PI3K regulatory subunit.</p>

<h2>General Summary of the Paper</h2>

<p>This paper reports the discovery and validation of a rare PIK3R1 W624R mutation in high-grade serous ovarian carcinoma (HGS-EOC). Using whole exome sequencing, copy number analysis, and pyrosequencing, the authors identified the mutation as truncal in both the original tumour and PDX lines. Functional validation through ex vivo PDTC drug testing and in vivo PDX treatment demonstrated susceptibility of PIK3R1 W624R-carrying tumours to PI3K/AKT/mTOR pathway inhibitors (buparlisib, alpelisib, dactolisib) but not to p110β-specific inhibitors. The study highlights the unique role of PDX models in establishing the actionability of rare driver mutations and supports integrating such models into precision oncology pipelines.</p>

<h2>Eligibility</h2>

<p>Eligible for inclusion: <strong>Yes</strong>  </p>

<h2>How Actionability is Understood</h2>

<p>Actionability is defined as the functional property of a mutation that (1) renders tumour cells dependent (“addicted”) to a specific pathway, (2) has a targeted therapeutic available, and (3) confers responsiveness to such treatment.  </p>

<blockquote>
  <p>“Mutations have also been defined as ‘actionable’, not only because their functional outcome makes carrier cells responsive to a targeted therapy, but also thanks to the availability of a specific targeted drug.” (p. 2)  </p>
</blockquote>

<blockquote>
  <p>The study uses PDX models “to validate low frequency mutations as biomarkers for targeted therapy” (p. 2).</p>
</blockquote>

<h2>What Makes Something Actionable</h2>

<ul>
<li><p>Functional impact on a key signalling pathway relevant to oncogenesis.  </p></li>
<li><p>Presence of a targeted drug that inhibits the altered pathway.  </p></li>
<li><p>Evidence from functional assays in relevant tumour models (PDX/PDTC).  </p></li>
<li><p>Truncal nature of the mutation (present in all tumour cells).  </p></li>
</ul>

<h2>How Actionability is Achieved / Operationalized</h2>

<ul>
<li><p><strong>Framework/Approach Name(s):</strong> PDX–PDTC functional validation pipeline for rare mutations.  </p></li>
<li><p><strong>Methods/Levers:</strong> Whole exome sequencing, pyrosequencing for allele frequency, pathway activation markers (P-S6, P-AKT), ex vivo viability and cytotoxicity assays, in vivo drug efficacy in PDX models.  </p></li>
<li><p><strong>Operational Steps / Workflow:</strong>  </p>

<p> 1. Identify candidate mutation via WES and CNA analysis.  </p>

<p> 2. Confirm truncal status via allele frequency in tumour and PDX.  </p>

<p> 3. Predict functional consequences via in silico analysis and structural modelling.  </p>

<p> 4. Test pathway activation via immunohistochemistry (P-S6).  </p>

<p> 5. Test drug sensitivity in PDTCs to multiple inhibitors.  </p>

<p> 6. Validate in vivo efficacy in PDX tumour growth and biomarker changes.  </p></li>
<li><p><strong>Data &amp; Measures:</strong> Allele frequency, GR metrics in viability assays, IHC quantification of Ki67 and P-S6, tumour volume in vivo.  </p></li>
<li><p><strong>Implementation Context:</strong> HGS-EOC PDX biobank.  </p></li>
</ul>

<blockquote>
  <p>“PDX model… invaluable for functional validation, as it allowed overcoming questionable assays in test tubes or in unrelated cell types.” (p. 2)  </p>
</blockquote>

<blockquote>
  <p>“PIK3R1 W624R carrying cells [were] addicted… to inhibitors of the PI3K/AKT/mTOR pathway.” (Abstract)</p>
</blockquote>

<h2>Dimensions and Attributes of Actionability (Authors’ Perspective)</h2>

<ul>
<li><p><strong>CL (Clarity):</strong> Yes — functional consequences demonstrated through targeted assays and clear drug-response metrics.  </p></li>
<li><p><strong>CR (Contextual Relevance):</strong> Yes — relevance to ovarian cancer context stressed; rare mutation validated in disease-matched models.  </p></li>
<li><p><strong>FE (Feasibility):</strong> Yes — presence of clinically available inhibitors; mutation is targetable.  </p></li>
<li><p><strong>TI (Timeliness):</strong> No explicit link.  </p></li>
<li><p><strong>EX (Explainability):</strong> Partial — mechanistic explanation offered but structural modelling inconclusive.  </p></li>
<li><p><strong>GA (Goal Alignment):</strong> Yes — aligns with precision oncology aim of matching mutations to therapies.  </p></li>
<li><p><strong>Other Dimensions Named by Authors:</strong> Truncality, pathway addiction.</p></li>
</ul>

<h2>Theoretical or Conceptual Foundations</h2>

<ul>
<li><p>Precision oncology model of “driver” vs. “passenger” mutations.  </p></li>
<li><p>Concept of mutation “addiction” to specific signalling pathways.  </p></li>
<li><p>Basket/umbrella trial rationale for cross-cancer therapeutic targeting.</p></li>
</ul>

<h2>Indicators or Metrics for Actionability</h2>

<ul>
<li><p>Mutation truncal status.  </p></li>
<li><p>Drug-response curves (GR metrics).  </p></li>
<li><p>Biomarker modulation (P-AKT, P-S6) upon inhibitor treatment.  </p></li>
<li><p>In vivo tumour growth delay and reduced proliferation index.</p></li>
</ul>

<h2>Barriers and Enablers to Actionability</h2>

<ul>
<li><p><strong>Barriers:</strong> Low frequency of mutation; inconclusive structural modelling; lack of prior functional characterisation in ovarian cancer.  </p></li>
<li><p><strong>Enablers:</strong> Availability of relevant inhibitors; PDX/PDTC models mimicking patient tumour biology; high allele frequency indicating truncality.</p></li>
</ul>

<h2>Relation to Existing Literature</h2>

<p>The authors note that while PIK3R1 mutations are common in other cancers, they are rare in HGS-EOC. Prior studies lacked functional validation in ovarian models. This study fills that gap, showing that a cSH2 domain mutation (previously unlinked to oncogenesis) can be actionable in this context.</p>

<h2>Summary</h2>

<p>This study identifies and functionally validates a rare PIK3R1 W624R mutation as actionable in high-grade serous ovarian carcinoma. Using a PDX–PDTC pipeline, the authors demonstrate that this truncal mutation activates the PI3K/AKT/mTOR pathway and renders tumour cells dependent on it. The mutation confers sensitivity to PI3K inhibitors (buparlisib, alpelisib, dactolisib) but not to p110β-specific inhibitors. Structural modelling could not fully explain the functional impact, underlining the need for experimental validation in relevant disease models. This work exemplifies how rare mutations in the “long tail” of cancer drivers can be prioritised and operationalised in precision oncology when robust functional models and therapeutic agents are available.</p>

<h2>Scores</h2>

<ul>
<li><p><strong>Overall Relevance Score:</strong> 82 — Clear conceptualisation of actionability with explicit definition, truncal mutation concept, and disease-context specificity.  </p></li>
<li><p><strong>Operationalization Score:</strong> 90 — Detailed, reproducible pipeline from mutation identification to functional validation and therapeutic testing.</p></li>
</ul>

<h2>Supporting Quotes from the Paper</h2>

<ul>
<li><p>“Mutations… defined as ‘actionable’, not only because their functional outcome makes carrier cells responsive to a targeted therapy, but also thanks to the availability of a specific targeted drug.” (p. 2)  </p></li>
<li><p>“PIK3R1 W624R carrying cells [were] addicted… to inhibitors of the PI3K/AKT/mTOR pathway.” (Abstract)  </p></li>
<li><p>“PDX model… invaluable for functional validation, as it allowed overcoming questionable assays in test tubes or in unrelated cell types.” (p. 2)  </p></li>
<li><p>“The PIK3R1 W624R #475 PDTCs… were sensitive to… buparlisib… alpelisib… dactolisib… but not… GSK2636771.” (p. 11)</p></li>
</ul>

<h2>Actionability References to Other Papers</h2>

<ul>
<li><p>COSMIC (CGCv84) database [28]  </p></li>
<li><p>DGidb drug–gene interaction database [31]  </p></li>
<li><p>References on PI3K/AKT/mTOR inhibitors in clinical development [20, 48–51]  </p></li>
<li><p>Prior functional studies on PIK3R1 mutations [32, 38–40]</p></li>
</ul>
